Valion Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
Monitoring Framework
Key Performance Indicators
Entolimod Manufacturing Scale-up Volume Quarterly50.0Target: Commercial scale-up and third-party CDMO revenue generation
Clinical Trial Enrollment (Sheba Medical Center Study) Quarterly0.0Target: 10 adult patients
Watch Items
- BARDA and U.S. Government Procurement ContractTrigger: Execution of a formal funding, procurement, or stockpiling agreementAction: Re-evaluate long-term cash runway and adjust valuation models to reflect non-dilutive revenue
- Ukraine Ministry of Health Regulatory ReviewTrigger: Formal decision under Ukraine's Regulatory Equivalency pathway (expected in 45 to 60 days from July 2026)Action: Assess international commercialization timeline and potential national reserve opportunities
- Cash Burn Rate and Capital AdequacyTrigger: Cash runway falling below 6 months or further highly dilutive private placementsAction: Review going concern risk and adjust the probability of the base-case scenario
Research as of 17 Jul 2026